Status:

RECRUITING

MicroRNA as Markers in Testicular Cancer

Lead Sponsor:

Haukeland University Hospital

Collaborating Sponsors:

Karolinska University Hospital

Sahlgrenska University Hospital

Conditions:

Testicular Germ Cell Cancer

Seminoma

Eligibility:

MALE

18-70 years

Brief Summary

The main objective of this study is establish the performance of miR371 in management of testicular cancer

Detailed Description

The main objective of the study is to asses the sensitivity and specificity of microRNA-371a-5p (miR371) in detection of viable testicular germ tumour cells. To assess the utility of miR371 at orchiec...

Eligibility Criteria

Inclusion

  • Patients with suspected testicular cancer, referred to orchiectomy.
  • Patients diagnosed with testicular germ cell cancer.
  • Age 18-70 years of age.
  • Must be able receive information and to consent.

Exclusion

  • Other prior or concomitant malignancy (other than testicular cancer).
  • Other diseases or conditions that hinder the ability to receive information and to participate in follow-up procedures.

Key Trial Info

Start Date :

December 31 2016

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2026

Estimated Enrollment :

350 Patients enrolled

Trial Details

Trial ID

NCT04914026

Start Date

December 31 2016

End Date

December 31 2026

Last Update

August 8 2022

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Haukeland University Hospital

Bergen, Norway, 5021

2

Haugesund Hospital

Haugesund, Norway, 5528

3

Oslo University Hospital

Oslo, Norway, 0379

4

University Hospital of North Norway

Tromsø, Norway, 9038